Page 1225 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1211

Ethinyl estradiol, 723f. See also Estrogen(s) Factor VII deficiency, 622t Ferrous sulfate, 595t, 605t
Ethionamide, 843t, 847 Factor VIIa, recombinant Ferumoxytol, 595, 605t
Ethosuximide, 428–429, 433t, 437t description of, 622t, 623, 624t Fesoterodine, 131. See also Muscarinic
Ethotoin, 419–420 warfarin reversal using, 616 receptor blockers
Ethyl alcohol, 382. See Ethanol Factor VIII deficiency, 621–623, 622t Fetal alcohol syndrome, 401
Ethylene glycol Factor IX deficiency, 621–623, 622t Fetal development, 1049, 1049f
description of, 405–406, 406t Factor Xa inhibitors, oral direct, 616–617 Fetal drug metabolism, 1048. See also
poisoning management for, 1041t, 1045 Factor XIII deficiency, 622t Pregnancy, pharmacology in
Ethylene oxide, 901 Fadrozole, 739 Fetal hemoglobin, 592b
Ethynodiol diacetate, 728t. See also Falciparum malaria treatment, 917, 937. Fexofenadine, 281, 282f, 283t, 296t.
Progestins See also Malaria drugs See also H 1 -receptor antagonists
Etidocaine, 470. See also Anesthetics, local Famciclovir Fibrates
Etidronate, 779f, 779–781 herpes simplex virus treated with, with bile-acid binding resins, 639
Etodolac, 645t, 647 865t, 867 description of, 634–635, 635f, 639t
Etomidate topical dermatologic, 1074 Fibric acid derivatives
anesthesia using, 450f, 450t, 455 varicella zoster simplex virus treated with bile-acid binding resins, 639
description of, 715 with, 865t, 867 description of, 634–635, 635f
Etoposide, 962t, 964 Familial combined hyperlipoproteinemia, Fibrinolysis, 611, 611f
Etravirine, 872t, 878 629t, 630, 631 Fibrinolytic inhibitors, 611f, 622t, 623,
Euphoria, 560 Familial combined hypertriglyceridemia, 624t
Eutectic mixture of local anesthetics 629t Fibrinolytics, 618–619, 624t
(EMLA), 471 Familial dysbetalipoproteinemia, 629t, 630 Fibroblast growth factor 23 (FGF23)
Everolimus, 986–987 Familial hypercholesterolemia, 629t, 630, bone homeostasis, 773, 773f, 777–778
Evidence, types of, 14b–15b 631f on gut, bone, and kidney, 778t
Evolocumab, 638, 995 Familial hypertriglyceridemia, 629t, 630 Fibroids, uterine, 677
Excitatory postsynaptic potential (EPSP), Familial ligand-defective apolipoprotein Fick’s law of diffusion, 8–9
35, 103, 103f, 371, 371f B-100, 629t, 630 Fidaxomicin, 896, 902t
Excitement, in general anesthesia, 446 Famotidine, 1089–1091. See also Filgrastim, 602t, 602–604, 603f, 606t
Exemestane, 739 H 2 -receptor antagonists Finasteride
Exenatide, 762, 769t Fansidar, 835, 926 antiandrogenic actions of, 743, 744f,
Exocrine glands, 307 Fasidotrilat, 310, 317t 745t
Exocrine pancreatic insufficiency, 1112 Fasudil, 313b dermatologic use of, 1085
Exocytosis, 8f, 9 angina pectoris treated with, 207, 210t Finerenone, 220, 266
Expectorants, 1125t pulmonary hypertension treated with, Fingolimod hydrochloride (FH), 989–990
Experimental physiology, 2 313b First-in-human studies, 14b
Exposure FDA, Food & Drug Administration, 15 First-pass effect
duration of, 1005 Febuxostat, 662–663 definition of, 58
intensity of, 1005 Feedback pathways, brain, 373 extraction ratio and, 48
quantity of, 1005 Feed-forward pathways, brain, 373 intestinal metabolism in, 58
routes of, 1005 FEIBA, 623 routes of administration in, alternative,
Expoxygenase products, 325–326 Felbamate, 425–426, 433t 48
Extensive metabolizer (EM), 68, 75t Felodipine First-pass elimination, 47–48
Extraction ratio (ER) angina pectoris treated with, 203t Fish tapeworms
first-pass effect and, 48 hypertension treated with, 187 niclosamide for, 943
formula for, 47 Female maturation, estrogens on, 724 praziquantel for, 944–945
Extrinsic factor, 596 Fenofibrate FK-binding protein (FKBP), 986
Eye description of, 634–635, 635f, 639t Flavin monooxygenase, 61t, 69
autonomic pharmacology of, 105b, 105f with reductase inhibitors, 639 Flecainide, 239t, 240t, 242, 251t
b receptors in, 148 Fenoldopam, 151, 154t, 186, 192t. See also Flexible regulation, 35
Ezetimibe, 637, 640t Sympathomimetics Flow-dependent elimination, 46
with bile-acid binding resins, niacin, and Fenoprofen, 645t Flucloxacillin, 83t, 84f, 84–85
reductase inhibitors, 639 Fentanyl. See also Opioid agonists Fluconazole
with reductase inhibitors, 639 description of, 555t, 567–568, 572t dermatologic, 1073
Ezogabine, 421, 433t, 437t transdermal, 564 description of, 857f, 858, 858t, 861t
Ferric carboxymaltose, 595, 605t Flucytosine, 855f, 856, 861t
F Ferric hexacyanoferrate, 1033 Fludarabine, 958t, 961
Factor V deficiency, 622t Ferrous fumarate, 595t, 605t Fludrocortisone, 709t, 715. See also
Factor V Leiden mutation, 611 Ferrous gluconate, 595t, 605t Corticosteroids, synthetic